These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38311833)

  • 21. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 25. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors.
    Durairaj C; Chakrabarti J; Ferrario C; Hirte HW; Babu S; Piha-Paul SA; Plotka A; Hoffman J; Shi H; Wang DD
    Clin Pharmacokinet; 2021 Jul; 60(7):921-930. PubMed ID: 33686631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
    Lasseter KC; Sologuren A; La Noce A; Dilzer SC
    Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment.
    Boinpally R; Weissman D
    Clin Pharmacol Drug Dev; 2023 Feb; 12(2):132-140. PubMed ID: 36504331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
    Lin S; Gong J; Canas GC; Winkle P; Pelletier K; LaBadie RR; Ginman K; Pithavala YK
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):235-245. PubMed ID: 35018553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
    Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
    Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
    Shaik N; LaBadie RR; Hee B; Chan G
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
    Guérard N; Zwingelstein C; Dingemanse J
    J Clin Pharmacol; 2017 Nov; 57(11):1425-1431. PubMed ID: 28618006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
    Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar Sinbaglustat.
    Melchior M; Dingemanse J; Alatrach A; Feldkamp T; Sidharta PN; Géhin M
    J Clin Pharmacol; 2021 Jul; 61(7):932-938. PubMed ID: 33368330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
    Ankrom W; Yee KL; Sanchez RI; Adedoyin A; Fan L; Marbury T; Preston RA; Iwamoto M; Khalilieh SG
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
    Samukawa Y; Haneda M; Seino Y; Sasaki T; Fukatsu A; Kubo Y; Sato Y; Sakai S
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):820-828. PubMed ID: 29693800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.